data + articles · 7 listed
newest 2025spec sheet13 rows
Tramadol is a centrally acting opioid analgesic used to treat moderate to moderately severe pain, set apart from typical opioids by a dual mechanism [1][2]. In addition to weakly activating the mu-opioid receptor, it inhibits the reuptake of the neurotransmitters serotonin and norepinephrine, so it also behaves somewhat like an antidepressant [2]. First marketed in the late 1970s and sold under names such as Ultram, it is a scheduled controlled substance in many countries.
- Relief of moderate acute or chronic pain
- Useful for some neuropathic pain
- Lower respiratory-depression risk than strong opioids at normal doses
- Mild mood lift from its serotonin and norepinephrine action
- Comes as tablets, drops, and once-daily extended-release forms
- Lower abuse ceiling than oxycodone or morphine, though not zero
- Common effects include nausea, dizziness, dry mouth, constipation, drowsiness, and headache
- It can lower the seizure threshold, and seizures have occurred even at recommended doses
- It can cause physical dependence, and withdrawal may last longer than with many other opioids
- Response varies with CYP2D6 genetics, and naloxone only partly reverses an overdose
Overview
Tramadol is a synthetic analgesic structurally related to codeine and morphine, classified as an atypical or centrally acting opioid [1]. It is supplied as a racemic mixture of two mirror-image enantiomers whose actions complement one another; one favors serotonin reuptake inhibition while the other favors norepinephrine reuptake inhibition, and both, together with an active metabolite, contribute to pain relief [1][2]. The compound was patented in the early 1970s by the German company Grünenthal and launched in 1977 as Tramal, later reaching the United States market in 1995 [2].
Tramadol is used for a wide range of acute and chronic pain, including postoperative, traumatic, and cancer-related pain, and it has been applied off-label to conditions such as fibromyalgia and premature ejaculation [3]. Its parenteral analgesic potency is roughly one-tenth that of morphine [1]. After it is taken by mouth, the liver enzyme CYP2D6 converts tramadol into O-desmethyltramadol, a metabolite with far greater affinity for the opioid receptor than the parent drug, so the response varies with a person's genetics; poor metabolizers may get little opioid effect, while ultrarapid metabolizers can experience unexpectedly strong effects [1][4]. It is available in many forms, including immediate-release and extended-release tablets, capsules, drops, and injectable solutions.
Because of its potential for misuse and dependence, tramadol is a controlled substance in many jurisdictions; it became a Schedule IV drug in the United States in 2014, and it is scheduled or restricted in the United Kingdom, Canada, Australia, and elsewhere [1]. Although historically promoted as carrying a lower risk than conventional opioids, it can cause genuine physical dependence, and its withdrawal may be prolonged and include both opioid and antidepressant-like features [1]. Notable hazards include a lowered seizure threshold, so seizures can occur even at recommended doses, and serotonin syndrome when it is combined with other serotonergic drugs, a risk that also makes monoamine oxidase inhibitors a contraindication [2][3].
Mechanism
Tramadol relieves pain through two distinct and complementary actions rather than a single opioid effect [1][2]. First, it and especially its liver-derived O-desmethyltramadol (called M1) act as agonists at the mu-opioid receptor, though the affinity of the parent drug for this receptor is low, thousands of times weaker than morphine [2]. The M1 binds far more strongly, so much of tramadol's opioid effect depends on conversion by the enzyme CYP2D6, whose activity varies from person to person [1][4].
Second, tramadol inhibits the reuptake of and in the spinal cord, raising the levels of these neurotransmitters in pathways that normally dampen the transmission of pain signals [1][2]. The two enantiomers of the racemic drug divide this labor: one preferentially blocks reuptake while the other preferentially blocks reuptake, and their combined action is synergistic [1]. This monoamine component explains why the opioid naloxone only partially reverses tramadol and why the drug can precipitate syndrome and lower the seizure threshold [2]. Tramadol has an elimination of about six hours, while the active persists somewhat longer [1].
receptor fingerprint
Mu-opioid receptor (via O-desmethyltramadol, M1)agonist
transporter (SERT)inhibits reuptake
transporter (NET)inhibits reuptake
CYP2D6 (metabolizing enzyme)substrate
Mu-opioid receptor (parent tramadol)partial agonist
Safetyrisks and cautions, not medical advice
Tramadol's biggest surprises are the non-opioid ones. It lowers the seizure threshold, and convulsions have been reported both in overdose and at ordinary therapeutic doses; risk climbs with higher doses, in people with epilepsy, and alongside other threshold-lowering drugs. Crucially, these seizures do not respond to naloxone and can actually be worsened by it, so they are managed with benzodiazepines like diazepam. Because it raises serotonin, tramadol can cause serotonin syndrome, especially when paired with SSRIs, SNRIs, MAOIs, triptans, or other serotonergic agents; MAOIs are an outright contraindication.
Its reliance on CYP2D6 makes its effects unpredictable; poor metabolizers get little relief, while ultrarapid metabolizers can overshoot into respiratory depression and overdose, which is part of why it is dangerous in young children. Like any opioid it can cause dependence, and coming off it is a double act of classic opioid withdrawal plus an atypical SNRI-like discontinuation with anxiety, restlessness, and brain zaps. Common side effects include nausea, dizziness, constipation, and sweating. The US DEA classifies tramadol as a Schedule IV controlled substance, and it is prescription-only in most countries.
Interactionsdocumented pairs only, not exhaustive
Tramadol is metabolized by CYP2D6 and CYP3A4 to produce its active metabolite M1. The most clinically significant documented interaction is pharmacodynamic; combined use of tramadol with SSRIs, SNRIs, and other serotonergic agents substantially increases the risk of serotonin syndrome [5]. A large FDA adverse event reporting system analysis found that the combination of tramadol with SSRIs carried a reporting odds ratio of 41.95 for serotonin syndrome [6].
Tramadol also inhibits serotonin reuptake via the (+)-enantiomer and norepinephrine reuptake via the (−)-enantiomer, so these effects add to those of reuptake inhibitors. Pharmacokinetically, tramadol is subject to CYP450-mediated interactions [7]. CYP2D6 poor metabolizers experience reduced analgesic efficacy. Interactions with nonopioid analgesics and detailed effects of CYP3A4 inducers and inhibitors on the active metabolite M1 are incompletely characterized.
Checking a whole stack? Run it through interactions + stacks.
Subjective profileweighing the evidence above
Useful for moderate and some neuropathic pain, and often chosen because it looks gentler than a strong opioid. That framing is misleading: it lowers the seizure threshold even at recommended doses, those seizures are not reversed by naloxone, and withdrawal can drag on longer than with other opioids.
Resources
No suppliers are provided for compounds like this. This entry is here for reference.
Research
- 1997first cited[Pharmacology of tramadol].
- 2025most recentSelective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-D…
- 1.Clinical pharmacology of tramadol.
- 2.[Pharmacology of tramadol].
- 3.Tramadol as an analgesic for mild to moderate cancer pain.
- 4.Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries (NCBI Bookshelf).
- 5.Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review.
- 6.Selective Serotonin Reuptake Inhibitors and Risk of Serotonin Syndrome as Consequence of Drug-Drug Interactions: Analysis of the FDA Adverse Event Reporting System.
- 7.Trends in Tramadol: Pharmacology, Metabolism, and Misuse.
7 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is tramadol a safe or 'weak' opioid?
It is weaker than morphine at the opioid receptor, but that label undersells it; tramadol can cause seizures, serotonin syndrome, dependence, and fatal overdose, so it deserves the same caution as any opioid.
Can tramadol cause seizures?
Yes. It lowers the seizure threshold, and convulsions have been reported at normal doses, not just in overdose; the risk grows with higher doses and with other threshold-lowering drugs. Naloxone does not fix these seizures and may worsen them, so benzodiazepines like diazepam are used instead.
When is tramadol dangerous with antidepressants?
Because tramadol raises serotonin, combining it with SSRIs, SNRIs, MAOIs, triptans, or other serotonergic drugs can trigger serotonin syndrome, a potentially life-threatening state of agitation, tremor, fever, fast heart rate, and muscle rigidity. MAOIs are an outright contraindication.
Why does tramadol work differently from person to person?
It relies on the liver enzyme CYP2D6 to become its strong M1 metabolite. Poor metabolizers get weak pain relief, while ultrarapid metabolizers make M1 quickly and can reach dangerous opioid levels at ordinary doses.
Is tramadol addictive?
Yes. It produces genuine opioid dependence, and stopping suddenly can bring both classic opioid withdrawal and an atypical SNRI-like discontinuation with anxiety, brain zaps, and restlessness; taper under medical guidance.
Adverse effects
- Common effects include nausea, dizziness, dry mouth, constipation, drowsiness, and headache
- It can lower the seizure threshold, and seizures have occurred even at recommended doses
- It can cause physical dependence, and withdrawal may last longer than with many other opioids
- Response varies with CYP2D6 genetics, and naloxone only partly reverses an overdose
Notes and cautions
- Combining it with SSRIs, SNRIs, MAOIs, or other serotonergic drugs can trigger serotonin syndrome